Brain scans reveal Ocrelizumab's impact on MS inflammation
NCT ID NCT04230174
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 26 times
Summary
This study looked at how the drug ocrelizumab changes brain inflammation in people with multiple sclerosis (MS). Researchers used special brain scans to measure inflammation before and after one year of treatment. The study included 22 adults with relapsing-remitting or progressive MS. The goal was to see if ocrelizumab reduces harmful immune activity in the brain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
Conditions
Explore the condition pages connected to this study.